GlassScriptPhysician profile
Oluwatomisin A Aluko
NPI 1245897602
$3,032.52
in general payments reported to CMS, 2019-2025
27 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2024: $787 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,865 · Gift: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,865.28 |
| Gift | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $446.38 | 2022-2025 | Evenity, Prolia, Tepezza |
| Dexcom, INC. | $364.38 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $273.89 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Ascendis Pharma Endocrinology INC | $251.39 | 2025 | Yorvipath |
| Corcept Therapeutics | $249.59 | 2024-2025 | Korlym |
| Tandem Diabetes Care, INC. | $177.43 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $160.85 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Ascensia Diabetes Care US INC. | $141.93 | 2025 | |
| Mannkind Corporation | $133.79 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $91.54 | 2024-2025 | |
| Radius Health, INC. | $91.11 | 2024-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $83.14 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $69.87 | 2024-2025 | Farxiga, Lokelma |
| Embecta Corp. | $66.32 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Bayer Healthcare Pharmaceuticals INC. | $61.48 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $61.31 | 2025 | Tirosint, Licart, Flector |
| Abbvie INC. | $57.67 | 2025 | |
| Sequel Med Tech, LLC | $54.59 | 2025 | Twiist |
| Globus Medical, INC. | $32.92 | 2025 | Senza |
| Alexion Pharmaceuticals, INC. | $32.84 | 2025 | Strensiq |
| Alvogen INC | $24.71 | 2024 | Teriparatide |
| Abbott Laboratories | $23.42 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Acella Pharmaceuticals, LLC | $16.68 | 2025 | NP Thyroid 60 |
| Antares Pharma, INC. | $16.64 | 2025 | Xyosted |
| Cequr Corporation | $15.85 | 2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $13.95 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oluwatomisin Aluko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.